(-0.07%) 5 474.75 points
(-0.11%) 38 776 points
(-0.03%) 19 915 points
(0.15%) $80.45
(1.26%) $2.82
(0.19%) $2 333.50
(-0.26%) $29.32
(-0.22%) $968.80
(0.00%) $0.931
(-0.19%) $10.63
(0.04%) $0.787
(-1.87%) $86.80
Live Chart Being Loaded With Signals
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia...
Stats | |
---|---|
Šios dienos apimtis | 195 333 |
Vidutinė apimtis | 441 795 |
Rinkos kapitalizacija | 53.09M |
EPS | $-0.00960 ( Q1 | 2024-03-26 ) |
Kita pelno data | ( $-0.0800 ) 2024-09-04 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.840 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00300 (0.47%) |
Tūris Koreliacija
BioLineRx Ltd. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
LULU | 0.963 |
NDRA | 0.953 |
EZGO | 0.946 |
SRNE | 0.944 |
CMTL | 0.943 |
DCFC | 0.938 |
NEOG | 0.934 |
SHC | 0.931 |
RKDA | 0.93 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
RFAIU | -0.98 |
IVCB | -0.956 |
WDC | -0.934 |
CCSB | -0.933 |
NEWZ | -0.929 |
WIRE | -0.929 |
LABP | -0.926 |
SWAV | -0.924 |
PAYS | -0.923 |
BCSA | -0.92 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
BioLineRx Ltd. Koreliacija - Valiuta/Žaliavos
BioLineRx Ltd. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $4.80M |
Bruto pelnas: | $174 000 (3.63 %) |
EPS: | $-0.940 |
FY | 2023 |
Pajamos: | $4.80M |
Bruto pelnas: | $174 000 (3.63 %) |
EPS: | $-0.940 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-654 000 (0.00 %) |
EPS: | $-0.370 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.600 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
BioLineRx Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.